Two-year Outcomes of Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration with “Observe before Treat-and-Extend” Method
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate 2-year outcomes of intravitreal aflibercept injection for neovascular age-related macular degeneration (nAMD) treated with “observe before treat-and-extend (O-TAE)” strategy in the real-world setting. Methods: This retrospective study included treatment-naive nAMD patients treated with aflibercept using O-TAE regimen and followed up for more than 2 years. Patients were observed bimonthly to check recurrence after three monthly loading injections. In case of recurrence, treatment was resumed using the TAE regimen starting from the fourth injection. In case of nonrecurrence, observation was continued. Best-corrected visual acuity (BCVA), central macular thickness (CMT), number of injections, TAE intervals, and proportion of recurrence after dry-up following three loadings were analyzed. Results: A total of 38 eyes of 34 patients were included. Follow-up period was 37.0 ± 11.0 months. BCVA by logarithm of minimal angle of resolution improved from 0.33 ± 0.29 at baseline to 0.24 ± 0.23 in the first year (p = 0.010) and 0.25 ± 0.22 in the second year (p = 0.054). CMT decreased significantly from 357.43 ± 74.53 μm at baseline to 269.62 ± 48.12 μm in the first year (p < 0.001) and 279.14 ± 54.64 μm in the second year (p < 0.001). Number of injections were 5.11 ± 1.69 in the first year and 3.84 ± 2.39 in the second year. The percentage of eyes with a TAE interval of ≥12 weeks was 37.0% in the first year and 34.4% in the second year. Of the 36 eyes that dried up after three loadings, 28 eyes (77.8%) recurred, and the average period of recurrence was 6.5 months. The remaining eight eyes (22.2%) had no recurrence during the mean follow-up period of 29.7 months. Conclusions: This study showed that the newly suggested O-TAE strategy can reduce the treatment burden significantly reducing the number of injections while improving BCVA and CMT in the first and second year.
Abstract
Purpose: To evaluate 2-year outcomes of intravitreal aflibercept injection for neovascular age-related macular degeneration (nAMD) treated with “observe before treat-and-extend (O-TAE)” strategy in the real-world setting. Methods: This retrospective study included treatment-naive nAMD patients treated with aflibercept using O-TAE regimen and followed up for more than 2 years. Patients were observed bimonthly to check recurrence after three monthly loading injections. In case of recurrence, treatment was resumed using the TAE regimen starting from the fourth injection. In case of nonrecurrence, observation was continued. Best-corrected visual acuity (BCVA), central macular thickness (CMT), number of injections, TAE intervals, and proportion of recurrence after dry-up following three loadings were analyzed. Results: A total of 38 eyes of 34 patients were included. Follow-up period was 37.0 ± 11.0 months. BCVA by logarithm of minimal angle of resolution improved from 0.33 ± 0.29 at baseline to 0.24 ± 0.23 in the first year (p = 0.010) and 0.25 ± 0.22 in the second year (p = 0.054). CMT decreased significantly from 357.43 ± 74.53 μm at baseline to 269.62 ± 48.12 μm in the first year (p < 0.001) and 279.14 ± 54.64 μm in the second year (p < 0.001). Number of injections were 5.11 ± 1.69 in the first year and 3.84 ± 2.39 in the second year. The percentage of eyes with a TAE interval of ≥12 weeks was 37.0% in the first year and 34.4% in the second year. Of the 36 eyes that dried up after three loadings, 28 eyes (77.8%) recurred, and the average period of recurrence was 6.5 months. The remaining eight eyes (22.2%) had no recurrence during the mean follow-up period of 29.7 months. Conclusions: This study showed that the newly suggested O-TAE strategy can reduce the treatment burden significantly reducing the number of injections while improving BCVA and CMT in the first and second year.
참고문헌 (33)
- GBD 2019 Blindness and Vision Impairment Collaborators, "Causes of blindness and vision impairment in 2020and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight:an analysis for the Global Burden of Disease Study", Lancet Glob Health, 9, pp.e144~e160 (2021)
- Sarwar S, "Aflibercept for neovascular age-related macular degeneration", Cochrane Database Syst Rev, 2, pp.CD011346~ (2016)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Brown GC, "A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States", Am J Ophthalmol, 223, pp.405~429 (2021)
- Holz FG, "Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration", Br J Ophthalmol, 99, pp.220~226 (2015)
- Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group, "The neovascular age-related macular degeneration database : multicenter study of 92 976ranibizumab injections : report 1 : visual acuity", Ophthalmology, 121, pp.1092~1101 (2014)
- Lad EM, "Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries", Am J Ophthalmol, 158, pp.537~543 (2014)
- Spaide R, "Ranibizumab according to need : a treatment for age-related macular degeneration", Am J Ophthalmol, 143, pp.679~680 (2007)
- Stewart MW, "Individualized treatment of neovascular age-related macular degeneration : what are patients gaining? or losing?", J Clin Med, 4, pp.1079~1101 (2015)
- Freund KB, "Treat-and-extend regimens with anti-VEGF agents in retinal diseases : a literature review and consensus recommendations", Retina, 35, pp.1489~1506 (2015)
- Augsburger M, "Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration : a comparative study", Graefes Arch Clin Exp Ophthalmol, 257, pp.1889~1895 (2019)
- Hatz K, "Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration : a comparative 12 Month study", Acta Ophthalmol, 95, pp.e67~e72 (2017)
- Chin-Yee D, "A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration", Br J Ophthalmol, 100, pp.914~917 (2016)
- Khachigian LM, "Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration", J Transl Med, 21, pp.133~ (2023)
- Huang CH, "Two-year real-world results for aflibercept using the treat-and-extend regimen in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy", Ophthalmol Ther, 13, pp.385~396 (2024)
- Jaggi D, "Aflibercept for age-related macular degeneration : 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy", Br J Ophthalmol, 106, pp.246~250 (2022)
- Gascon P, "Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol : the Armada study", Eur J Ophthalmol, 32, pp.356~363 (2022)
- Ishibashi K, "Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients", Ther Adv Ophthalmol, 13, pp.2515841420984586~ (2021)
- Maruko I, "Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration : a prospective study", Ophthalmol Retina, 4, pp.767~776 (2020)
- Jeong S, "Modified observe-and-plan regimen using aflibercept for neovascular age-related macular degeneration", Acta Ophthalmol, 99, pp.e1535~e1536 (2021)
- Ohji M, "Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration : 52-and 96-week findings from ALTAIR : a randomized controlled trial", Adv Ther, 37, pp.1173~1187 (2020)
- Mitchell P, "Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration : the ARIES study : a randomized clinical trial", Retina, 41, pp.1911~1920 (2021)
- Chaikitmongkol V, "Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy : consensus and recommendations from the Asia-Pacific Vitreo-retina Society", Asia Pac J Ophthalmol(Phila), 10, pp.507~518 (2021)
- Ohnaka M, "A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 255, pp.657~664 (2017)
- Vofo BN, "Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration", BMJ Open Ophthalmol, 7, pp.e001180~ (2022)
- Charles J, "Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen : results from a prospective observational study", Taiwan J Ophthalmol, 13, pp.219~224 (2023)
- Mantel I, "Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen", Br J Ophthalmol, 98, pp.1192~1196 (2014)
- Parvin P, "Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept", Graefes Arch Clin Exp Ophthalmol, 255, pp.2127~2134 (2017)
- Subhi Y, "Injection burden and treatment intervals of aflibercept in observe-andplan regimen for neovascular age-related macular degeneration", Acta Ophthalmol (2024)[DOI]
- Choi YJ, "One-year outcomes of a treat-and-extend of ranibizumab for naive exudative age-related macular degeneration : retrospective analysis", J Korean Ophthalmol Soc, 62, pp.939~947 (2021)
- Inoue M, "Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration", Am J Ophthalmol, 169, pp.95~103 (2016)
- Kikushima W, "Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration", Sci Rep, 7, pp.44020~ (2017)